Donald A. Bergstrom - 16 Jun 2021 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Executive Vice President, Head of Research and Development
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
16 Jun 2021
Net transactions value
-$1,251,630
Form type
4
Filing time
17 Jun 2021, 19:38:59 UTC
Previous filing
22 Jun 2022
Next filing
30 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $174,037 +42,242 +55% $4.12 119,483 16 Jun 2021 Direct F1
transaction RLAY Common Stock Sale $1,425,668 -42,242 -35% $33.75 77,241 16 Jun 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -42,242 -14% $0.000000 253,456 16 Jun 2021 Common Stock 42,242 $4.12 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
F2 This transaction was executed in multiple trades at prices ranging from $33.09 to $34.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Remarks:

Executive Vice President, Head of Research and Development